FSLR
78
-3
URI
56
-3
VTR
64
-6
BXP
38
-4
MOS
30
-6
PLD
40
-8
PNC
41
-3
AVB
62
-5
SYK
57
-5
TGNA
59
-5
FFIV
57
-4
AIV
55
-3
NWL
29
-3
PPG
64
-5
TXT
70
-5
M
50
-2
FLS
68
-7
CTAS
61
-3
MA
57
-5
RF
34
-3
FSLR
78
-3
URI
56
-3
VTR
64
-6
BXP
38
-4
MOS
30
-6
PLD
40
-8
PNC
41
-3
AVB
62
-5
SYK
57
-5
TGNA
59
-5
FFIV
57
-4
AIV
55
-3
NWL
29
-3
PPG
64
-5
TXT
70
-5
M
50
-2
FLS
68
-7
CTAS
61
-3
MA
57
-5
RF
34
-3
Financhill
Back

Cyclacel Pharmaceuticals 10K Form

Sell
15

CYCC
Cyclacel Pharmaceuticals

Last Price:
2.05
Seasonality Move:
-13.89%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CYCC News And Ratings

See the #1 stock for the next 7 days that we like better than CYCC

CYCC Financial Statistics

Sales & Book Value

Annual Sales: $420K
Cash Flow: $-483K
Price / Cash Flow: 0
Annual Sales: $-1.67
Price / Book: 0

Profitability

EPS (TTM): -22.30000
Net Income (TTM): $-19.7M
Gross Margin: $1.9M
Return on Equity: -365.17%
Return on Assets: -149.29%

Cyclacel Pharmaceuticals Earnings Forecast

Key Cyclacel Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 18 years for CYCC is 97.74%.
  • The Selling, General & Administrative Expenses for CYCC have been equal to 1,599.52% of Gross Profit Margin.
  • The Research & Development expenses have been 4,560.71% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of CYCC is -5,370.24% of Total Revenues.
  • Per Share Earnings over the last 26 years have been positive in 21 years.

Cyclacel Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CYCC
CUSIP: 23254L
Website: cyclacel.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0.58
Quick Ratio: 0.54

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CYCC Technical Analysis vs Fundamental Analysis

Sell
15
Cyclacel Pharmaceuticals (CYCC) is a Sell

Is Cyclacel Pharmaceuticals a Buy or a Sell?